Pentazocine
As of the edition of 20 October 2026, Pentazocine is a small molecule: marketed, first approved in 1982 (US); acts on SIGMAR1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Talwin
- First approved
- 1 January 1982 (US)
- Approvals on record
- 5 in 1 region
- Holder of the most recent approval
- Sanofi; 2 holders in all
- Registered trials
- 4, 0 stopped early
- Disease areas
- Nervous system; Mental health
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Pentazocine.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| SIGMAR1 | Sigma non-opioid intracellular receptor 1 | Q99720 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 4 |